Human-in-the-Loop + AI: A Pragmatic Path Forward for Pharma Commercialization

In a recent industry webinar, senior leaders from across the life sciences spectrum gathered to discuss the evolving role of artificial intelligence in commercialization. While the promise of AI is undeniable, the consensus was clear: In pharma, technology must serve as an enabler — not a disruptor — for the people who drive strategy, compliance and patient impact.

Abid Rahman, senior vice president of innovation at EVERSANA, offered a grounded perspective on how AI can be deployed responsibly and effectively in pharma. His key insight? AI must be designed with humans at the center. This isn’t just a philosophical stance — it’s a practical requirement in a highly regulated, high-stakes industry.

EVERSANA’s newly launched AI Agency Platform, built in partnership with Google, exemplifies this approach. It’s not a tool for automation alone — it’s a framework for human-in-the-loop intelligence, where AI accelerates content creation, insight generation and engagement strategies, but always under the guidance of experts who understand therapeutic context, regulatory nuance and brand integrity.

What Senior Pharma Leaders Are Thinking

Throughout the webinar, several themes emerged that are particularly relevant for large pharmaceutical manufacturers:

• AI is not a replacement for humans. Leaders emphasized that while AI can streamline workflows and surface insights, it cannot replace the strategic thinking required for global commercialization. The value lies in augmenting — not automating — human decision-making.
• Compliance is nonnegotiable. Any AI solution must be built with governance in mind. The risk of noncompliant content or messaging is too great to leave unchecked. Human oversight is essential to ensure outputs meet regulatory standards and brand guidelines.
• Data quality is a limiting factor. AI is only as good as the data it’s trained on. Several panelists noted that fragmented, siloed or outdated data can undermine AI’s effectiveness. Platforms that integrate proprietary, real-world and commercial data offer a distinct advantage.
• Speed must be balanced with strategy. While AI can dramatically reduce time to market, leaders cautioned against sacrificing strategic depth for speed. The human-in-the-loop model allows for rapid iteration without losing sight of long-term objectives.

A Use Case in Action

Abid shared how EVERSANA’s AI Agency Platform is already being used to support global launch planning, omnichannel content development and HCP engagement strategies. In one example, the platform helped a client generate and refine hundreds of personalized content assets in days — not weeks — while ensuring every piece was reviewed by medical, legal and brand teams before deployment.

This kind of scalable, compliant and context-aware capability is what pharmaceutical manufacturers need as they navigate increasingly complex global markets.

Reimagining the Agency Model

The takeaway from the webinar was clear: AI in pharmaceutical commercialization must be both intelligent and intentional. The human-in-the-loop model isn’t a compromise — it’s a competitive advantage. It ensures that AI serves the business, the brand and, ultimately, the patient.

For senior pharma leaders, this is an opportunity to rethink the traditional agency model. With EVERSANA’s AI Agency Platform, commercialization becomes more agile, data-driven and scalable — without sacrificing the human insight that drives meaningful outcomes.

Now is the time to reimagine your agency model. Explore how AI can elevate your commercial strategy intelligently, responsibly and with purpose. Learn more at www.eversana.ai/agency or connect with our team to start the conversation.